Annual Meeting, investigators presented a late-breaking study focused on surgical aortic valve replacement (SAVR) following ...
Several medical societies supported extending Medicare coverage for TAVR to patients with asymptomatic aortic stenosis, but some physicians and rival Medtronic said more data is needed.
SAN FRANCISCO -- Better indicators of high-grade atrioventricular (AV) conduction system abnormalities following transcatheter aortic valve replacement (TAVR) could be gleaned from an intraprocedural ...
MedPage Today on MSN
Aortic Stenosis Mortality Increased After Broad FDA Approval of TAVR
Delays in diagnosis, long waits for operations may explain trend ...
LOUISVILLE, Colo., Dec. 1, 2023 /PRNewswire/ -- The initial findings of Colibri Heart Valve's multicenter high-risk TAVR EU pilot study were presented at PCR London Valves November 20 th, 2023. The ...
Intermediate-risk patients who received transcatheter aortic valve replacement, known as TAVR, with the latest-generation valve fared better than patients receiving traditional surgical aortic valve ...
Repeat transcatheter aortic valve replacement (TAVR) with a balloon-expandable valve is effective in treating a failed first transcatheter valve, with low procedural risks and with clinical outcomes ...
The novel findings, published today in the peer-reviewed journal The Lancet, are significant because recent randomized clinical trials have shown that TAVR is a meaningful treatment option for both ...
Edwards pushes CMS to expand Medicare TAVR coverage to asymptomatic patients, sparking controversy among physicians over ...
SAN FRANCISCO — Left atrial appendage occlusion (LAAO) at the time of transcatheter aortic valve replacement (TAVR) using the WATCHMAN 2.5 device (Boston Scientific) is feasible and non-inferior to ...
Please provide your email address to receive an email when new articles are posted on . Atrial fibrillation is associated with increased risk for bleeding and stroke in patients undergoing TAVR. Left ...
Medtronic will invest $90M in Anteris Technologies for DurAVR TAVR device development, contingent on a $200M IPO.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results